- Investing Ideas
- /
- Australian Pharmaceuticals & Biotech Potentially Undervalued Companies
Australian Pharmaceuticals & Biotech Potentially Undervalued Companies
Results
44
Companies with a Value score of at least 3, ordered by Value score
44 companies
Mayne Pharma Group
Market Cap: AU$416.8m
A specialty pharmaceutical company, focuses on the commercialization of women’s health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally.
MYX
AU$5.10
7D
0.7%
1Y
11.1%
Percheron Therapeutics
Market Cap: AU$10.9m
Engages in the research and development of novel antisense pharmaceuticals for cancer and rare diseases in Australia.
PER
AU$0.01
7D
-9.1%
1Y
-90.0%
Neuren Pharmaceuticals
Market Cap: AU$2.5b
A biopharmaceutical company, develops drugs for the treatment of neurological disorders.
NEU
AU$19.71
7D
-2.2%
1Y
37.5%
Acrux
Market Cap: AU$5.7m
Develops and commercializes generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally.
ACR
AU$0.014
7D
0%
1Y
-75.0%
Genetic Signatures
Market Cap: AU$60.2m
Operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas.
GSS
AU$0.27
7D
3.9%
1Y
-60.4%
Vita Life Sciences
Market Cap: AU$136.3m
A healthcare company, engages in formulating, packaging, distributing, and selling vitamins and supplements in Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China.
VLS
AU$2.44
7D
-1.6%
1Y
n/a
Percheron Therapeutics
Market Cap: AU$10.9m
Engages in the research and development of novel antisense pharmaceuticals for cancer and rare diseases in Australia.
PER
AU$0.01
7D
-9.1%
1Y
-90.5%
Genetic Signatures
Market Cap: AU$60.2m
Operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas.
GSS
AU$0.26
7D
2.0%
1Y
-60.9%